SCHEMBL29171685

SCHEMBL29171685

O=c1cc(Cl)c2ccc(Br)cc2[nH]1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
METAP2 P50579 1/20 0.47
PTGES O14684 2/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
PDPK1 O15530 1/20 0.43
TNKS2 Q9H2K2 2/20 0.42
MAPT P10636 1/20 0.41
CDK9 P50750 2/20 0.41
CDK5 Q00535 2/20 0.41
CAMK2A Q9UQM7 2/20 0.41
AR P10275 1/20 0.41
CCNT1 O60563 1/20 0.41
CCNB2 O95067 1/20 0.41
CCNE2 O96020 1/20 0.41
CDK1 P06493 1/20 0.41
CDK4 P11802 1/20 0.41
CCNB1 P14635 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30759515 1.00 TP53 (0.47) TP53SMN1; SMN2METAP2PTGESCYP3A4
SCHEMBL20838314 0.85 AR (0.51) PTGESCYP2C9CYP2C19PDPK1MAPT
SCHEMBL2796184 0.81 TP53 (0.70) TP53SMN1; SMN2CYP2C9PDPK1LMNA
SCHEMBL29410772 0.81 TP53 (0.70) TP53SMN1; SMN2CYP2C9PDPK1LMNA
SCHEMBL2798886 0.79 KDM4E (0.62) TP53SMN1; SMN2METAP2CYP2C19TNKS2
SCHEMBL29892996 0.79 KDM4E (0.62) TP53SMN1; SMN2METAP2CYP2C19TNKS2
SCHEMBL2798042 0.78 TNKS2 (0.50) TP53SMN1; SMN2PDPK1TNKS2MAPT
SCHEMBL29831055 0.78 KDM4E (0.59) METAP2CDK9CDK5CAMK2AAR
SCHEMBL14796728 0.78 KDM4E (0.59) METAP2CDK9CDK5CAMK2AAR
SCHEMBL25738522 0.78 METAP2 (0.47) TP53SMN1; SMN2METAP2PDPK1TNKS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250059205-A1 Heterocyclic Compounds and Methods of Use AMGEN INC. (US) 2025-02-20 US disclosed
CN-117561063-A Heterocyclic compounds and methods of use 安进公司 2024-02-13 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250059205-A1 Heterocyclic Compounds and Methods of Use KRAS, NRAS, HRAS TP53 4/4885SMN1; SMN2 1990/4885METAP2 4402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.